Search

Search Results

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  3482

  PDF: 1352

  HTML: 9140

  Untitled: 238

  Untitled: 130

  Untitled: 127

  Untitled: 126

  Untitled: 142

  Untitled: 284

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2685

  PDF: 1343

  HTML: 3019

  Cover Letter: 159

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277294

  PDF: 1682

  HTML: 3801

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2531

  PDF: 650

  HTML: 861

• DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

  Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu

  e2023008

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.008

  1062

  PDF: 1052

  HTML: 390

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2028

  PDF: 955

  HTML: 1956

  Characteristic of study group: 149

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  2757

  PDF: 1338

  HTML: 327

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3209

  PDF: 1459

  HTML: 2627

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3047

  PDF: 1372

  HTML: 3955

• Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

  Toshifumi Takahashi

  e2020005

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.005

  1575

  PDF: 1039

  HTML: 241

• FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY

  Jyotsna Kapoor, Narendra Agrawal, Rayaz Ahmad, Sanjeev Kumar Sharma, Anshul Gupta, Dinesh Bhurani

  e2015013

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.013

  1747

  PDF: 980

  HTML: 1740

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4147

  PDF: 2523

  HTML: 2168

• Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature

  Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina

  e2018027

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.027

  2842

  PDF: 874

  HTML: 296

• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

  Judit Demeter, Julia Weisinger, Zsolt Nagy

  e2021022

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.022

  1207

  PDF: 419

  HTML: 188

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  82

  PDF: 41

  Html: 4

• DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML

  Istemi SERIN, Mustafa PEHLIVAN, Kursat OZDILLI, Fatma OGUZ SAVRAN, Gaye TOMATIR, Sacide PEHLIVAN

  e2021020

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.020

  910

  PDF: 316

  HTML: 164

• Coexistence of P190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report

  najmaldin saki, Mohammad Seghatoleslami, Neda Ketabchi, Alireza Ordo, Javad Mohammadi-Asl, Neda Golchin

  e2016002

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.002

  2906

  PDF: 769

  HTML: 2432

• THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

  Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto

  e2025023

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.023

  826

  PDF: 824

  HTML: 73

• CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY

  Lodovico Balducci

  e2014037

  2014-05-31

  https://doi.org/10.4084/mjhid.2014.037

  2718

  PDF: 1011

  HTML: 2995

• IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

  Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica

  e2021062

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.062

  981

  PDF: 393

  HTML: 126

• NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

  Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera

  e2020083

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.083

  1313

  PDF: 1054

  HTML: 151

• SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA

  Naveen Gupta, Manoranjan Mahapatra, Tulika Seth, Seema Tyagi, Sudha Sazawal, Renu Saxena

  e2021004

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.004

  1398

  PDF: 407

  HTML: 178

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  1831

  PDF: 1113

  HTML: 1598

• Interstitial pneumonia triggered by H1N1 influenza A virus as the initial presentation of chronic myeloid leukemia

  Zhan Su, Feng Wang

  e2025063

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.063

  730

  PDF: 386

  HTML: 98

  Suppl. Files: 272

• SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19

  Elisabetta Abruzzese, Luigia Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo de Fabritiis

  e2020031

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.031

  3003

  PDF: 1444

  HTML: 372

• Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

  Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

  e2016016

  2016-02-20

  https://doi.org/10.4084/mjhid.2016.016

  2742

  PDF: 622

  HTML: 1885

  figure 1: 124

  figure 2: 132

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  69

  PDF: 50

  Html: 5

• THE PROGNOSTIC SIGNIFICANCE OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM IN EGYPTIAN CHRONIC MYELOID LEUKEMIA THE PROGNOSTIC SIGNIFICANCE OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM IN EGYPTIAN CHRONIC MYELOID LEUKEMIA

  Enas A Dammag, Nahla A.M. Hamed, Professor, Nabil A El Halawani, Professor, Heba S Kassem, Professor, Mona W Ayad, Professor

  e2020004

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.004

  1847

  PDF: 907

  HTML: 274

• LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

  Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

  e2011021

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.021

  1386

  PDF: 704

  HTML: 808

  jdoe, table 2 infections CML .doc: 142

  jdoe, table 1 infections CML .doc: 135

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  2834

  PDF: 1120

  HTML: 3432

• A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fabrizio Pane

  e2014010

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.010

  3032

  PDF: 1262

  HTML: 4049

• HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19

  Stefano Botti, Nicola Serra, Fausto Castagnetti, Sabina Chiaretti, Nicola Mordini, Gianpaolo Gargiulo, Laura Orlando

  e2021011

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.011

  1286

  PDF: 483

  HTML: 192

• Fecal microbiota transplantation as a salvage therapy for concomitant resistant digestive graft versus host disease and cryptosporidiosis in a patient post hematopoietic stem cell transplant : about a case

  Thomas Finotto, Carole Chevenet, Amandine Fayard

  e2025035

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.035

  830

  PDF: 660

  HTML: 50

• FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE

  Ghaleb Elyamany, Mohamed Awad, Omar Alsuhaibani, Kamal Fadalla, Omer Al Sharif, Mohammad Al Shahrani, Fahad Alabbas, Abdulaziz Al-Abulaaly

  e2014038

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.038

  1655

  PDF: 902

  HTML: 7135

• PROGNOSTIC VALUE OF PROTEASE ACTIVATED RECEPTOR-1 IN EGYPTIAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Adel Abd Elhaleim Hagag

  e2014029

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.029

  1184

  PDF: 702

  HTML: 2235

• COMPARATIVE EVALUATION OF BONE MARROW ASPIRATE WITH TREPHINE BIOPSY IN HEMATOLOGICAL DISORDERS AND DETERMINATION OF OPTIMUM TREPHINE LENGTH IN LYMPHOMA INFILTRATION

  Surbhi Goyal, Usha Rani Singh, Usha Rusia

  e2014002

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.002

  1715

  PDF: 965

  HTML: 51691

• ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

  Daniel Olson, Abraham Tareq Yacoub, Gelenis Domingo, John Norman Greene

  e2014068

  2014-08-28

  https://doi.org/10.4084/mjhid.2014.068

  1641

  PDF: 653

  HTML: 2060

  Untitled: 135

  Untitled: 125

  Untitled: 127

  Untitled: 125

  Untitled: 127

  Untitled: 146

  Untitled: 143

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1374

  PDF: 914

  HTML: 83

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2050

  PDF: 697

  HTML: 719

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3401

  PDF: 1539

  HTML: 11070

  Figures Haase: 152

• PROGNOSTIC VALUE OF BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC GENE EXPRESSION IN EGYPTIAN CHILDREN WITH ACUTE MYELOID LEUKEMIA

  adel abd elhaleim hagag

  e2015033

  2015-04-19

  https://doi.org/10.4084/mjhid.2015.033

  1911

  PDF: 762

  HTML: 1077

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3619

  PDF: 1080

  HTML: 1622

• CMV Reactivations During and after Letermovir Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation: a Single-Center Experience.

  Edoardo Olivari

  e2025079

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.079

  214

  PDF: 110

  Html: 16

• COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center.

  Afadil Adam

  e2020070

  2020-08-29

  https://doi.org/10.4084/mjhid.2020.070

  1503

  PDF: 1031

  HTML: 247

• A STUDY ON THE EXPRESSION OF BCR-ABL TRANSCRIPT IN MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) CASES USING THE REVERSE TRANSCRIPTASE POLYMERASE REACTION ASSAY (RT-PCR) AND ITS CORRELATION WITH HEMATOLOGICAL REMISSION STATUS POST INITIAL INDUCTION THERAPY

  Prateek bhatia, Jogeshwar Binota, Neelam Varma, Deepak Bansal, amita trehan, Ram Kumar Marwaha, Pankaj Malhotra, Subhash Varma

  e2012024

  2012-05-03

  https://doi.org/10.4084/mjhid.2012.024

  1210

  PDF: 715

  HTML: 4988

  INSTITUTE PUBLICATION COMMITTEE APPROVAL: 120

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2303

  PDF: 752

  HTML: 8668

  Efremov 1: 158

  Efremov 2: 136

• CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

  Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand

  e2017048

  2017-08-16

  https://doi.org/10.4084/mjhid.2017.048

  1791

  PDF: 709

  HTML: 911

  Untitled: 162

• EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS

  Salvatore Giacomo Morano, Lorenzo Coppola, Roberto Latagliata, Paola Berneschi, Antonio Chistolini, Alessandra Micozzi, Corrado Girmenia, Massimo Breccia, Gregorio Brunetti, Angela Matturro, Giovanni Rosa, Pietro Guerrisi, Franco Mandelli, Roberto Foà, Giuliana Alimena

  e2014011

  2014-02-18

  https://doi.org/10.4084/mjhid.2014.011

  1963

  PDF: 762

  HTML: 1510

• TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION

  Elisabetta Abruzzese

  e2019025

  2019-04-26

  https://doi.org/10.4084/mjhid.2019.025

  1743

  PDF: 996

  HTML: 155

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4530

  PDF: 1622

  HTML: 2648

  Untitled: 158